Phase II study of FR-104 in patients with rheumatoid arthritis
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
Price : $35 *
At a glance
- Drugs FR 104 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 07 Dec 2017 According to an OSE Immunotherapeutics media release, this trial is planned to initiate by the end of 2018.
- 12 Sep 2017 New trial record
- 07 Sep 2017 According to an OSE Immunotherapeutics, the company expected to initiate this study in 2018.